Today's Date: September 25, 2023
Joint Statement on the Importance of Comprehensive, Multidisciplinary and Collaborative Care for Patients with Peripheral Artery   •   Wondershare FamiSafe 7.0 safeguarding Children with AI   •   Reactive Technologies’ Grid Inertia Measurement Tech to Enable Offshore Wind Rollout in Taiwan   •   Guidewire Optimistic About New Direction of California Insurance   •   Shift4 Partners with Give Lively to Offer Powerful Fundraising Solution to Nonprofits   •   Sixth Annual War Heroes on Water Charity Sportfishing Tournament Kicks Off, Bringing Hope and Healing to Combat-Wounded Veterans   •   Intel Editorial: Intel Addresses Semiconductor Workforce Shortage   •   Statement by Minister Khera on Yom Kippur   •   France Announces €40 Million in New Funding to Education Cannot Wait at Global Citizen Festival   •   Statement by the Prime Minister on Yom Kippur   •   THE BLACK WOMEN'S AGENDA, INC. HOSTS 46TH ANNUAL SYMPOSIUM TOWN HALL & AWARDS LUNCHEON   •   2023 Gangnam Festival to be Held in Gangnam, the Heart of K-pop   •   65+ Populations in Upstate NY's 4 Largest Regions Surging, Getting Poorer; AARP NY to Meet with Local Leaders   •   2023 GLOBAL CITIZEN FESTIVAL SEES $240 MILLION COMMITMENT FROM FRANCE AND NORWAY TO COMBAT THE GLOBAL FOOD CRISIS   •   A Meyers Manx Collaboration with Artist Sage Vaughn Contributes $200,000 to Arts Education Fundraiser   •   PRAIRIE VIEW A&M UNIVERSITY ANNOUNCES 2023-2024 WRITER-IN-RESIDENCE ATTICA LOCKE   •   Live Good Inc. Celebrates Diversity and Unity: A Beacon of Progress in the Spirit of Crissy Field, Angel Island and the Buffalo   • collaborates with   •   Student Entrepreneurs from Yale University Win Prestigious $1 Million 2023 Hult Prize   •   No more oil, gas and coal. Two nation-states join growing bloc of countries calling for a Fossil Fuel Non-Proliferation Treaty
Bookmark and Share

IgGenix Demonstrates Potential for an IgG4 Monoclonal Antibody-based Approach to Treating Peanut Allergy

SOUTH SAN FRANCISCO, Calif. , June 09 /Businesswire/ - IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to directly address allergic disease, today announced advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. These data will be presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, taking place in Hamburg, Germany on June 9-11, 2023.

Highlights from the EAACI Data

  • Nearly all peanut-specific IgE antibodies discovered from peanut-allergic individuals were high affinity, with many exhibiting double-digit picomolar affinity.
  • Select monoclonal IgG4 antibodies, re-engineered from human IgE antibodies, were able to inhibit allergic plasma IgE from binding recombinant Ara h 2 in vitro, and also inhibit whole peanut-mediated mast cell and basophil activation.
  • These IgG4 antibodies have the potential to form the basis of a therapeutic drug candidate exhibiting strong potency and efficacy in vitro, ex vivo, and in vivo.
  • This potential new paradigm for food allergy treatment could allow for protection within days of subcutaneous administration without the adverse events and long treatment duration associated with daily allergen administration.

“Peanut allergy is an increasingly prevalent unmet medical need that affects children and adults worldwide. There remains a need for a safe and efficacious therapeutic option with a rapid onset of action that protects against accidental allergen exposure and improves quality of life,” said Derek Croote, PhD, Co-Founder and Chief Technical Officer of IgGenix. “Through an unbiased human IgE discovery platform, IgGenix has created a powerful foundation from which to generate high-affinity IgG4 antibodies that bind to immunodominant allergens and epitopes on those allergens. These insights provide a potential path to a new standard of care for preventing severe allergic reactions.”

Title: Treating Peanut Allergy with an IgG4 Monoclonal Antibody-based Approach

Authors: Croote D., Wong J. J.W., Creeks P., Chung CP. B., Aruva V., Mabery E., Kaur A., Romero J., Grossman J., Thomas G.R., Lowman H.B.

Presenter: Derek Croote, PhD

The abstract can be accessed here.

About IgGenix

IgGenix is a privately held antibody discovery and development company taking a revolutionary approach to directly address severe allergies. Through our proprietary SEQ SIFTER™ discovery platform, developed from foundational research of co-founders Stephen Quake, Kari Nadeau, and Derek Croote of Stanford University, we isolate and re-engineer fully human, high-affinity, allergen-specific antibodies designed to block and prevent the allergic cascade. By targeting common immunodominant allergens and their most important epitopes across the patient population, we intend to treat allergic pediatric and adult patients alike across severe food and environmental allergies. This novel approach may prevent life-threatening allergic reactions, saving lives and reducing the constant fear that affects millions of people living with severe allergies.

STORY TAGS: Conference, Trade Show, Product/Service, California, Health, Infectious Diseases, Health Technology, Clinical Trials, Research, Science, Biotechnology, Germany, Europe, United States, North America,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News